EuroBiotech: More Articles of Note


> Zambon completed the acquisition of Breath Therapeutics. The takeover gives Zambon control of a phase 3 treatment for a rare fatal respiratory disease. Release 

> Transgene received U.K. regulatory clearance to trial its TG6002 oncolytic virus. Statement 

> BiomX secured itself a U.S. stock listing through a deal with Chardan Healthcare Acquisition. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Nasdaq told Motif Bio that it no longer meets the minimum requirements for listing. Motif Bio has until mid-January to regain compliance. Statement 

> The AMR Centre struck a deal with Shionogi for anti-virulence program COT-143. The plan is to run clinical trials of the asset next year. Release 

> Novo Holdings’ Repair impact fund invested $10 million in Curza and Spero. Statement 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.